PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-73.23%
Negative net income growth while AVGO stands at 32.35%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-0.44%
Negative yoy D&A while AVGO is 0.66%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
8050.00%
Some yoy growth while AVGO is negative at -716.67%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-16.67%
Negative yoy SBC while AVGO is 0.40%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
601.24%
Well above AVGO's 155.46% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
382.08%
AR growth well above AVGO's 90.99%. Michael Burry would fear inflated sales or less stringent credit controls vs. competitor.
-225.64%
Negative yoy inventory while AVGO is 86.55%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
48.94%
A yoy AP increase while AVGO is negative at -129.03%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
346.96%
Growth well above AVGO's 377.48%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
2900.00%
Some yoy increase while AVGO is negative at -1059.38%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
12.02%
Operating cash flow growth at 50-75% of AVGO's 18.30%. Martin Whitman would worry about lagging operational liquidity vs. competitor.
-24.19%
Negative yoy CapEx while AVGO is 8.63%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
24.19%
Less M&A spending yoy vs. AVGO's 14766.67%, reducing near-term risk. David Dodd would confirm the firm is not missing out on a strategic deal that competitor might exploit.
-19.05%
Negative yoy purchasing while AVGO stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
-14.13%
We reduce yoy sales while AVGO is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-25.26%
Both yoy lines negative, with AVGO at -300.00%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-84.02%
We reduce yoy invests while AVGO stands at 253.49%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
113.16%
Stock issuance far above AVGO's 60.98%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
-8.62%
We cut yoy buybacks while AVGO is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.